Novel Therapies in Advanced Renal Cell Carcinoma

被引：24

作者：

Ivanyi, P. ^{[1
]}

Winkler, T. ^{[1
]}

Ganser, A. ^{[1
]}

Reuter, C. ^{[1
]}

Gruenwald, V ^{[1
]}

机构：

[1] Hannover Med Sch, Klin Hamatol Hamostaseol Onkol & Stammzelltranspl, D-30625 Hannover, Germany

来源：

DEUTSCHES ARZTEBLATT INTERNATIONAL | 2008年 / 105卷 / 13期

关键词：

renal cell cancer; kinase inhibitor; sorafenib; sunitinib; molecular targeted therapy;

D O I：

10.3238/arztebl.2008.0232

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Sorafenib and Sunitinib are the first tyrosine kinase inhibitors licensed for the treatment of advanced renal cell carcinoma. In contrast to conventional chemotherapy, targeted therapies have distinct and specific side effects. Methods: Selective review in Medline and the data base of the American Society of Clinical Oncology on the treatment and side effects of tyrosine kinase inhibitors in renal cell carcinoma, drawing on the authors' own experience. Results and discussion: Tyrosine kinase inhibitors are characterized by a variety of uncommon side effects, such as lassitude, mucosal inflammation and skin changes. The detection and treatment of adverse events are critical for interdisciplinary cancer treatment in order to ensure patients' safety. This article offers an overview of the unwanted effects of drug therapy in the management of renal cell carcinoma.

引用

页码：232 / U15

页数：7

共 28 条

[21] Targeted therapy in advanced colon cancer:: the role of new therapies [J].

Tabernero, J ;

Salazar, R ;

Casado, E ;

Martinelli, E ;

Gómez, P ;

Baselga, J .

ANNALS OF ONCOLOGY, 2004, 15 :55-62

[22]

Tamaskar IR, 2007, J CLIN ONCOL, V25

[23] Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma [J].

Tsai, Kun-Ying ;

Yang, Chih-Hsun ;

Kuo, Tseng-tong ;

Hong, Hong-Shang ;

Chang, John W. C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (36) :5786-5788

[24] Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition [J].

Verheul, Henk. M. W. ;

Pinedo, Herbert M. .

NATURE REVIEWS CANCER, 2007, 7 (06) :475-485

[25] Mechanisms of hypertension associated with BAY 43-9006 [J].

Veronese, ML ;

Mosenkis, A ;

Flaherty, KT ;

Gallagher, M ;

Stevenson, JP ;

Townsend, RR ;

O'Dwyer, PJ .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) :1363-1369

[26]

Wolter P, 2007, NEW ENGL J MED, V356, P1580

[27] Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity [J].

Wong, Elaine ;

Rosen, Lee S. ;

Mulay, Marilyn ;

VanVugt, Andy ;

Dinolfo, Melissa ;

Tomoda, Chisato ;

Sugawara, Masahiro ;

Hershman, Jerome M. .

THYROID, 2007, 17 (04) :351-355

[28]

Zimmer M, 2004, MOL CANCER RES, V2, P89

← 1 2 3 →